This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Discover the crucial years to consider for retirement planning. Equip yourself with strategies for a successful retirement.
21,887 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Is Rivian a millionaire-maker stock or a high-risk punt? This guide dives into the catalysts, margins, and scenarios ...
Can Netflix grow from its current scale to a trillion-dollar market value? This article breaks down the unlikely path...
Oracle is set to report its June quarter as AI demand tests the cloud backbone. Backlog and RPO could reveal real app...
Small modular reactors could redefine electricity costs and energy security. This guide breaks down the investment th...
Real estate cycles linger, but today’s price pressures aren’t a carbon copy of 2008. Learn how Ken McElroy analyzes c...
Nvidia has built an AI powerhouse, but its stock sits at a valuation that invites scrutiny. This guide breaks down wh...
Solana attracts developers with speed and low fees. This article examines whether the bold prediction: solana will re...
Two big reasons explain why the fear around IBM's COBOL future might be overstated. This piece breaks down why COBOL ...
A SpaceX AI push could rewrite how we think about tech bets. If spacex just spent billion, investors should watch how...
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Richtech Robotics stock fell sharply in June after the company disclosed restatements. This guide breaks down what ha...